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a  b  s  t  r  a  c  t
Infection  with  dengue  virus  is  a major  public  health  problem  in the  Asia-Paciﬁc  region and  through-
out  tropical  and  sub-tropical  regions  of  the world.  Vaccination  represents  a major  opportunity  to
control  dengue  and  several  candidate  vaccines  are  in development.  Experts  in dengue  and  in  vac-vailable online 22 August 2011
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sia-Paciﬁc
cine  introduction  gathered  for a  two  day  meeting  during  which  they  examined  the  challenges
inherent to the introduction  of  a  dengue  vaccine  into  the  national  immunisation  programmes  of  coun-
tries  of  the  Asia-Paciﬁc.  The  aim  was to  develop  a series  of  recommendations  to reduce  the  delay
between  vaccine  licensure  and  vaccine  introduction.  Major  recommendations  arising  from  the  meet-
ing  included:  ascertaining  and  publicising  the  full burden  and  cost  of  dengue;  changing  the perception
of  dengue  in  non-endemic  countries  to help  generate  global  support  for dengue  vaccination;  ensuring
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high  quality  active  surveillance  systems  and  diagnostics;  and  identifying  sustainable  sources  of funding,
both to support  vaccine  introduction  and  to  maintain  the  vaccination  programme.  The  attendees  at  the
meeting were  in agreement  that  with  the introduction  of  an effective  vaccine,  dengue  is  a disease  that
could be controlled,  and  that in order  to ensure  a vaccine  is  introduced  as rapidly  as  possible,  there  is a
need to start  preparing  now.
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. Introduction
Dengue is a major public health concern throughout tropical and
ub-tropical regions of the world. It is the most rapidly spreading
osquito-borne viral disease, with a 30-fold increase in worldwide
ncidence over the last 50 years [1]. It is estimated that there are
ore than 50 million dengue infections each year and almost half
he world’s population live in countries in which dengue is endemic
1,2]. While dengue is a global concern, with a steady increase in
he number of countries reporting dengue, currently close to 75%
f the global dengue burden is borne by the Asia-Paciﬁc region [1].
Attempts to control dengue are focused on control of the
osquito vector [3]. Integrated vector management programmes
ave been shown to be effective in reducing total numbers of the
ector [4]. However, many vector control programmes have little
o no effect on dengue incidence [5] and those that are successful
an have difﬁculties with sustainability [6]. The limitations of vec-
or control include the cost of maintaining control programmes, the
ifﬁculty of destroying all mosquitoes in an area, and the movement
f mosquitoes across borders.
Given  the signiﬁcant and increasing burden of dengue, the
imitations of current control measures and the fact that disease
reatment is limited to supportive care, it is not surprising that
 dengue vaccine has been a priority of the World Health Orga-
ization (WHO) for a number of years [7]. Currently, there are a
umber of candidate dengue vaccines in development including
ecombinant, live attenuated, inactivated, DNA, and viral-vector
accines, with several undergoing clinical evaluation [7,8]. The
ost advanced of these candidates has recently entered Phase III
rials [9–11].
A  dengue vaccine should be ﬁrst introduced in countries where
countries  [12]. Previous vaccine introductions have taught us that
the key is to plan early [13]. This report presents a series of recom-
mendations for the rapid introduction of a dengue vaccine into the
national immunisation programmes (NIPs) of high disease burden
countries of the Asia-Paciﬁc.
2.  Dengue v2V and the Asia-Paciﬁc Meeting
The Dengue v2V initiative is a global scientiﬁc forum of experts
in dengue and public health, established in 2009 to lay the ground-
work for the rapid introduction of a dengue vaccine, focussing
on candidate vaccines in advanced stages approaching licensure
[14]. Its goals are to establish the human and economic costs
of dengue, raise awareness of the beneﬁts of vaccination, pro-
vide recommendations and guidance for vaccine introduction, and
advocate funding for broad access to dengue vaccination [14]. At
the 1st Dengue v2V Asia-Paciﬁc Meeting, held in Singapore from
30 November to 1 December 2010, the challenges inherent to the
introduction of a dengue vaccine into the NIPs of high disease bur-
den countries of the Asia-Paciﬁc were considered in light of the
lessons learned from previous vaccine introductions. Participants
at the meeting included experts in dengue, vaccine introduction
and regional vaccination programmes (see acknowledgments for a
full list of participants). The aim was to develop a series of recom-
mendations to reduce the lag time from vaccine licensure to vaccine
introduction.
3. Supporting vaccine adoption
Due to differences in climate, geography, urbanisation, socio-
economic status and population movement, there are considerable
Open access under CC BY-NC-ND license.he disease burden is greatest. Many of these are developing coun-
ries, which pose unique challenges to the introduction of a new
accine that in the past have led to signiﬁcant delays, even for vac-
ines which had already been successfully introduced in developedintra- and inter-country variations in dengue epidemiology in the
Asia-Paciﬁc region. Variations include the affected age groups, case
fatality rate, predominant serotype(s) and incidence rates. Further-
more, considerable differences in diagnosis and reporting systems
ine 29
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an limit the ability to make meaningful comparisons between
ountries. Southeast Asian national surveillance systems differ in
he case deﬁnitions used, ages surveyed, reporting requirements,
se of vector surveillance and the use of sentinel surveillance in
ddition to passive surveillance [15].
Passive surveillance is based on the reporting of conﬁrmed or
uspected cases encountered by health care workers. However, as
ost dengue cases are ambulatory, and not always seen by health
are workers, this system results in signiﬁcant under-reporting.
nder-reporting also results from the lack of a universally appli-
able or uniformly applied case deﬁnition [16]. Improving the
vailability and reliability of diagnostics for dengue is a major pri-
rity. Recent recommendations from the Asia-Paciﬁc and Americas
engue Prevention Boards (organised by the Dengue Vaccine Initia-
ive Consortium) include: making the reporting of dengue manda-
ory, use of electronic reporting systems, application of minimum
eporting requirements and sharing of expertise and data [15].
.1.  Health economics
To  obtain support from governments and global decision-
akers, a dengue vaccine must be shown to be cost-effective. This
equires accurate data on the economic costs of dengue. Dengue
s responsible for an annual estimated global burden of 750,000
isability-adjusted life years (DALY) [6,17,18]. A study across eight
ountries in Asia and Latin America estimated that the mean cost
er hospitalised case of dengue is US$571, of which 76% was  direct
osts and 24% indirect costs [19]. For ambulatory cases the mean
ost per case was US$248, of which 28% was direct costs and
2% indirect costs [19]. Another study estimated the total cost of
engue illness across the Americas (based on data from 2000 to
007) at US$2149.8 million per year, with a total of 72,772 DALY
ost [17]. Ambulatory cases accounted for 73% of the costs, hos-
italised cases 24%, and deaths 3% [17]. A comprehensive review
f health economic studies of dengue burden has recently been
ublished [20].
Such  cost studies face two main challenges: (i) it is difﬁcult to
ncorporate all of the costs of a case of dengue, and (ii) incidence
f dengue is considerably under-estimated. Expansion factors are
sed to adjust for the under-reporting of cases and provide esti-
ates of the true extent of the dengue burden [21]. Expansion
actors of 10–27 in Puerto Rico [22], 6 in Panama [23] and 21.3
n Nicaragua [24] have been reported. While different expansion
actors for different countries might be expected given differences
n surveillance systems, the wide variation observed calls for a sys-
ematic and comprehensive analysis of dengue under-reporting.
ndeed, reliable expansion factors will be essential to calculate the
ull cost of dengue.
The  threshold for vaccine cost-effectiveness recommended by
he WHO  is a cost per DALY saved of three times the annual per
apita gross domestic product (GDP) [25]. For dengue-endemic
ountries in the Asia-Paciﬁc region this threshold is approximately
S$3000. The cost-effectiveness of a dengue vaccine in Southeast
sia was calculated assuming a two-dose schedule and differ-
nt potential prices per dose [26,27]. At US$10 per dose, and an
ssumed dengue haemorrhagic fever (DHF) incidence of 72 cases
er 100,000 population per year, the cost-effectiveness ratio was
stimated at US$1212 per DALY saved, which is signiﬁcantly below
he US$3000 threshold.
It  may  be beneﬁcial to select a discrete dengue outbreak, such
s the recent outbreak in Martinique, and examine all the asso-
iated costs. This could then be more broadly applied to better
nderstand the total costs of dengue. The indirect costs that are
ypically unaccounted for include the cost of disruption to health
are services (caused by the inﬂux of dengue cases), and the cost of (2011) 9417– 9422 9419
decreased tourism, shipping, transport, and commerce due to fears
of the disease spreading.
3.2.  The human burden of dengue
The impact of dengue on patients and their families is signiﬁcant,
both economically and in terms of quality of life. The economic cost
disproportionately falls on the poor, particularly in countries where
most costs are covered by the patient. A study in Cambodia showed
that patients with dengue cover, on average, 78% of the total cost
and 63% of the direct medical cost [28]. In a study in Thailand, 47%
of patients with dengue could not afford to visit a reputable medical
provider, 14% could not afford treatment, and 17% had to borrow
money to cover the cost of illness [29]. Other studies in Cambodia
show how these costs are a continuing burden to the poor [30], with
the majority (62%) still unable to repay their debts up to one year
later [31]. There is also a signiﬁcant drop (>50%) in the quality of
life of both children and adults with dengue, which does not return
to baseline until 12–16 days after onset of illness which is almost
twice the duration of fever [32].
To raise the proﬁle of dengue among governments and global
decision-makers, which will be essential to secure funding for vac-
cine introduction, it will be necessary to publicise the full extent
of the human burden of dengue. The morbidity caused by dengue
should be highlighted and attempts made to move the global focus
away from simply considering mortality statistics. While the mor-
tality statistics for dengue are lower than for some other diseases
considered a global health priority, the human impact of dengue
morbidity is profound and, if better conveyed, persuasive. In par-
ticular, the impact of dengue on communities and its psychological
impact on patients and families are often ignored.
3.3. Computational modelling
Computational modelling is an additional tool to support the
decision-making process. It has proven to be highly advantageous
in dengue research, for example in mapping the movement of the
dengue virus from urban centres [33] and identifying the causes
of the upwards shift in the average age of patients with dengue
in some countries [34]. Each dengue-endemic country should have
the opportunity to run its own  modelling programs, however both
human (skilled technicians/programmers) and material (sufﬁcient
computational power) resources are currently lacking. This limita-
tion may  be overcome by establishing broadly applicable protocols
and sharing data, expertise and equipment. The use of common pro-
tocols will additionally facilitate comparisons and meta-analyses.
Finally, it is important that policymakers and their advisors be edu-
cated in the interpretation of computational models so that they
may fully understand the information and use it as part of their
decision-making process.
A  series of workshops to train suitably skilled people in running
computational models could be an effective way to establish new
modelling groups based in dengue-endemic countries. Interested
groups from dengue-endemic countries, including a decision-
maker, a dengue expert and a professional computational analyst,
could approach groups such as the Vaccine Modeling Initiative
(VMI) [35] to obtain open source software, advice and expertise,
and perhaps most importantly, access to the computational power
required. Regional workshops, where this information is shared,
could accelerate this process and also ensure collaboration between
all parties and the use of consistent protocols across groups. In
return, these groups would provide local data and parameters for
the models, validation of the modelling results against local histor-
ical data, a link between data generation and decision making, and
country ownership of the endeavour.
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. Implementing dengue vaccination
Vaccine introduction strategies should be tailored to national
equirements, taking into account existing NIPs, dengue epidemi-
logy, and regulatory restrictions. NIPs are well established in the
sia-Paciﬁc region and have proved successful in reducing the
urden of many infectious diseases. The best approach for incor-
orating a dengue vaccine into the NIPs of Vietnam, Indonesia,
he Philippines, Malaysia, and Thailand, was considered, assuming
based on the most advanced vaccine candidate) a three-dose vac-
ination regimen (baseline, 6 months and 12 months) for children
rom the age of 9 months. At the current time the proposed vacci-
ation schedule does not perfectly correspond to any of the NIPs in
he region. After the introduction of a dengue vaccine, as more is
earnt about the vaccine’s characteristics, it may  become possible
o alter the vaccination schedule to better ﬁt existing programmes
nd capabilities. The initial introduction, however, will most likely
e based on the schedule speciﬁed in the vaccine’s product proﬁle.
ossible approaches to facilitate this include: national vaccination
ays, school-based vaccination, and opportunistic vaccination (tak-
ng advantage of individuals receiving medical care to vaccinate at
he same time).
.1.  Logistics and infrastructure
Lessons  can be learnt from the introduction of other vaccines
n developing countries. During the introduction of rotavirus vac-
ine in Latin America for example, lessons were learnt in relation
o programmatic feasibility, cold chain systems, information sys-
ems for coverage monitoring, training and supervision, monitoring
f adverse events following immunisation (AEFI), vaccine supply
nd ﬁnancial sustainability [36]. These illustrated the importance
f having precise national plans to ensure, in particular, the techni-
al, programmatic and ﬁnancial feasibility of vaccination [36]. With
espect to dengue vaccine introduction, countries should develop
etailed logistical plans considering: catch-up immunisation, fore-
asting of supply needs, information systems requirements (record
eeping) and requirements for safe disposal of consumables. These
lans need to be speciﬁc for a dengue vaccine and its unique chal-
enges.
It has been estimated that 2.4–3.5 billion dengue vaccine doses
ould be needed in the ﬁrst ﬁve years after global introduction [37].
t will be crucial to ensure and demonstrate that vaccine supply
eeds can be met, particularly as a new vaccine will, at least ini-
ially, likely have a single manufacturer. Ultimately, decentralised
roduction of the vaccine could help to address these concerns.
.  Establishing long-term effectiveness and safety
.1.  Vaccine effectiveness
As  dengue vaccines become available, it will be essential to
easure the impact of their introduction. This will be achieved
sing established surveillance systems or by implementing post-
icensing effectiveness studies. If existing surveillance systems are
sed, many will need to be reorganised for this purpose, with
mproved reporting, adequate case investigation, and strengthened
nfrastructure. The implementation of speciﬁc surveillance activi-
ies such as sentinel networks and the expanded use of data from
ospitals, emergency rooms and laboratories could also serve to
mprove current systems..2.  Herd immunity
There  is a risk that vaccination against dengue will simply lead
o an increase in the age of peak incidence rather than broad (2011) 9417– 9422
herd  immunity. For example, in Singapore it is thought that a
vector-control-driven reduction in herd immunity in older peo-
ple ultimately led to increased dengue incidence in this population
who were more susceptible to clinically signiﬁcant disease [38].
Requirements to determine herd immunity are likely to differ from
one country to the next, and perhaps even within different areas or
communities within countries. Ultimately, strategies to determine
herd immunity will need to be tailored to each country, and in this
respect it will be critical to share data, and establish best practices
and consistency of reporting.
5.3.  Antibody dependent enhancement
Antibody dependent enhancement (ADE) is an in vitro obser-
vation that has been proposed to explain the increased risk of
severe disease both in the case of secondary infection and in infants
infected at the age of 6–9 months. In the ﬁrst case the enhanc-
ing antibodies would be non-neutralizing cross reactive antibodies,
while in the second case the enhancing antibodies would be mater-
nal antibodies that have waned to sub-neutralizing levels [39–41].
In the context of vaccination, two questions must be raised with
respect to the ADE theory; (i) will infection be enhanced if it occurs
in an individual before the completion of the full vaccination reg-
imen, and (ii) will an infection be enhanced in an individual some
time after vaccination due to waning immunity.
Clinical trials of the lead dengue vaccine candidate which are
closely monitored for the appearance of any ADE, of which there
has been no sign to date [11], will be the key to answering the ﬁrst of
these questions, but monitoring should continue well beyond vac-
cine introduction. Principally this will be to ensure that an increased
incidence of severe dengue does not emerge in the vaccinated pop-
ulation, but it could also serve to ensure accurate data are available
to address concerns or refute any claims about vaccine-related ADE
should cases arise.
5.4.  Pharmacovigilance
Establishing effective pharmacovigilance systems will be essen-
tial to accurately monitor the safety of a dengue vaccination
programme; this will be particularly important in countries that are
among the ﬁrst to adopt the vaccine. Certain conditions can poten-
tially be mistaken for AEFI. For example, leptospirosis or infection
with Rickettsia may  be mistaken for viscerotropic or neurotropic
disease, which is an extremely rare adverse event with the TFV
17D yellow fever vaccine (which forms the backbone of the cur-
rent lead candidate dengue vaccine [9]) [42]. There is therefore a
need for good differential diagnostic capacity at the country level,
with training of physicians in the recognition and diagnosis of these
illnesses. There is also a need for comprehensive background data
on potential adverse events such as viscerotropic or neurotropic
disease to respond to any perceived increase in incidence.
6.  Demonstration projects
Demonstration  projects are studies conducted in some coun-
tries after registration to support vaccine introduction activities
a step beyond licensure (but short of full scale introduction) and
help convince local authorities of the effectiveness of a vaccine and
the feasibility of vaccination [43]. The ongoing introduction of the
human papillomavirus (HPV) vaccine provides an example of the
usefulness of demonstration projects [44]. In Vietnam, formative
research identiﬁed the suitability of established delivery systems
and the receptiveness of policymakers to an HPV vaccine [45]. At
the same time it identiﬁed gaps in the cold chain system and public
concerns about vaccination which needed to be addressed.
ine 29 (2011) 9417– 9422 9421
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Box 1: Recommendations to prepare for dengue vaccine
introduction.
• Document  and publicise the true human and economic costs
of dengue.
• Ensure high quality surveillance systems and diagnostics so
that reliable background data can be generated.
• Generate  and share applications and protocols in diag-
nostics, surveillance, efﬁcacy studies and computational
modelling.
• Identify countries or regions for initial vaccine implementa-
tion based on existing capabilities and data.
• Individual  countries should start developing detailed logisti-
cal plans for dengue vaccine introduction.
• Implement  educational programmes for health care workers,
decision-makers and the public.
• Identify  sustainable sources of funding.
• Dengue-endemic  countries need to take ownership of theS.K. Lam et al. / Vacc
There are a number of complex issues surrounding dengue vac-
ination which highlight the importance of demonstration projects
43]. Speciﬁc sites which could be considered for demonstration
rojects include sentinel sites, urban centres, high-risk regions,
egions with well established NIPs, schools, and island commu-
ities. Any speciﬁc project should examine programme feasibility
ith respect to training and logistics together with vaccine effec-
iveness and issues related to AEFI and catch-up vaccination. While
ational programmes should consider the need for, and feasibil-
ty of, demonstration projects, it should not be necessary for every
ountry to run separate projects. Projects in one country could be
pplicable to other countries in the region.
. Education
During the introduction of the rotavirus vaccine in Latin America
ome countries did not allow sufﬁcient time to train all health care
orkers in vaccine administration, leading to uncertainty regarding
ossible contraindications and AEFI, reconstitution and administra-
ion, the interval between doses and minimum/maximum ages for
dministration [36]. For the successful introduction of a dengue
accine, comprehensive education programmes will need to be
n place and enough time must be taken to ensure that they
re completed. Programmes for NIP managers, vaccine providers,
aediatricians, other clinicians and nurses, and the general pub-
ic will be required. In addition, it will be important to educate
olicymakers on the extent of the dengue burden, the increasing
pread of dengue and the cost-effectiveness of a dengue vac-
ine. It will also help to train decision-makers, and those that
dvise them, in the understanding of computational models and
emonstration projects so that they might fully understand the
ata generated.
Given the potential controversies that surround every vaccine,
ogether with those unique to a dengue vaccine, expert advisory
odies with the ability to offer second opinions and advice should
e established. These advisory bodies will be able to support health
are workers and programme managers at the time of vaccine intro-
uction by providing informed responses to issues and concerns
ased on up-to-date information. Such a body would be able to
oordinate responses to ensure that only the most accurate infor-
ation is shared. A proactive communication strategy targeting
accine providers, authorities, clinicians and the public will also
e essential to manage potential myths and controversies. These
ay include concerns about a genetically modiﬁed vaccine, the risk
f ADE, other potential severe AEFIs (both real and misattributed),
edia misinformation, public rumour and coincidental events dur-
ng vaccine introduction (including dengue outbreaks).
.  Funding
Adequate funding will be essential to support the effective intro-
uction of a dengue vaccine. There are two key funding issues
o be addressed: (i) obtaining initial funding for vaccine intro-
uction, and (ii) establishing sustainable funding to support an
ngoing vaccination programme. Initial funding will need to cover
ll associated costs of vaccine introduction outlined above, includ-
ng logistics, vaccine supply, education, and surveillance costs.
unding for an ongoing vaccination programme will need to cover
ngoing maintenance of these requirements and, potentially, the
xpansion of the programme, including catch-up vaccination.
To  secure funding it will be critical to demonstrate the cost-
ffectiveness of dengue vaccination. Convincing data showing that
 hepatitis B vaccine was cost-effective were required before it
as introduced into the NIPs of developing countries [46]. Pre-
iminary analyses strongly suggest that dengue vaccination woulddisease and redeﬁne how dengue is viewed globally.
be cost-effective [26,27]; however, there is a need to generate
country-speciﬁc data and share it with decision-makers.
Given the wide-ranging costs and the immediate need for some
of the projects recommended in this report to either start or accel-
erate, governments of dengue-endemic countries should consider
assigning and securing funding now. Funding from a range of public
and private organisations should be considered including both tra-
ditional and innovative funding sources. At the same time, funding
from the global community will be essential. Unfortunately, while
dengue is a high priority in endemic countries, it is a low prior-
ity among decision-makers in the global health community, whose
priority is typically those diseases with the highest mortality. It
is critical that the global public health community starts to view
dengue as the major public health concern that it is.
9.  Summary of recommendations
The  collected meeting recommendations highlight the impor-
tance of preparing for dengue vaccine introduction now (see Box
1 for a summary of recommendations). It will be necessary to
document and publicise the true human and economic costs of
dengue. Under-reporting of dengue remains a signiﬁcant problem
so comprehensive analyses in different regions need to be per-
formed to quantify expansion factors. To support these efforts and
to prepare for requirements during and after vaccine introduction,
there is a need to ensure that high quality active surveillance sys-
tems and diagnostics are introduced so as to gather more detailed
and representative background data. To facilitate comparisons and
meta-analyses, toolkit applications and protocols in diagnostics,
surveillance and computational modelling that can be easily shared
and applied in different countries/regions should be developed and
disseminated.
Initial introduction of a dengue vaccine should be in a coun-
try or region with effective surveillance capabilities, where reliable
data are already available, and where there is the ability to con-
duct high quality pharmacovigilance studies. Regardless, each
dengue-endemic country should develop detailed logistical plans
for dengue vaccine introduction, including how to incorporate
a dengue vaccine into existing vaccination schedules and other
requirements unique to a dengue vaccine.
A series of educational programmes for health care workers,
decision-makers and the public should be planned and imple-
mented where required. These would include continuing, and
enhanced, training of physicians in the diagnosis of dengue, training
health care workers in logistical aspects of vaccine implementation,
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nd preparation for potential issues in order to be ready to address
ublic concerns as they arise.
It will be critical to identify sustainable sources of funding, both
o support vaccine introduction and to maintain the vaccination
rogramme. To achieve this, ownership and advocacy of dengue
isease and dengue control measures by individual countries will
e critical. Dengue-endemic countries have an increasingly strong
oice on the world stage; they should use it to redeﬁne how dengue
s viewed by the rest of the world.
0. Conclusions
The consensus at the meeting was that while dengue is currently
 major global public health problem, with the introduction of an
ffective vaccine it is a disease that can be controlled. It will be cru-
ial to change the perception of dengue in non-endemic countries,
here much of the funding may  need to originate, and publicise
he full burden and cost of dengue. The prospect of a vaccine for
engue being available in the near future is encouraging, but in
rder to ensure that it is introduced successfully, and as rapidly as
ossible, there is a need to start preparing now.
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